β-catenin/CBP-IN-1 (CBP/β-catenin inhibitor) is a potent and selective CBP/β-catenin inhibitor, extracted from the patent WO2014092154A1. β-catenin/CBP-IN-1 has the potential for the study of liver fibrosis induced by hepatitis virus[1].
[1]. Takenao Odagami, et al. Prevention or treatment agent for hepatic fibrosis. Patent WO2014092154A1.
















